- centos7搭建shadowsock
- Investors
- English
- linux安装shadowsock
- 日本語
佛跳墙2025永久破解版
For our lead product, Imeglimin, preparations are underway for a New Drug Application in Japan. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.
View Our Candidates
佛跳墙2025永久破解版
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
佛跳墙2025永久破解版
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
佛跳墙2025永久破解版
佛跳墙2025永久破解版
Japanese New Drug Application (J-NDA) for Imeglimin is supported by an extensive preclinical and clinical program, including positive results from the Phase 3 TIMES program in over 1,100 patients in Japan Imeglimin…
Read this Press Release: Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma佛跳墙2025永久破解版
Poxel completed a capital raise of EUR 17.7 million (USD 19.4 million) to accelerate development of PXL770 and PXL065 in NASH and to pursue early-stage opportunities for pipeline growth from its…
Read this Press Release: Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2025佛跳墙2025永久破解版
Shareholders approved all proposed resolutions LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for…
Read this Press Release: Poxel Announces Results from June 24, 2025 Ordinary Annual and Extraordinary General Meeting
佛跳墙2025永久破解版
European Association for the Study of the Liver 2025 International Liver Congress
